SCHEMBL3929008

SCHEMBL3929008

CCN(CC)C(=O)Cc1cccc(NC(=O)OC(C)(C)C)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.52
GLS O94925 1/20 0.39
MAPK8 P45983 1/20 0.39
CCR2 P41597 1/20 0.39
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
CHRNB2 P17787 2/20 0.38
CHRNB4 P30926 2/20 0.38
CHRNA3 P32297 2/20 0.38
CHRNA4 P43681 2/20 0.38
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
PDE5A O76074 1/20 0.36
LCK P06239 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP17A1 P05093 1/20 0.36
SCN9A Q15858 1/20 0.36
NR1I3 Q14994 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5692965 0.84 SMN1; SMN2 (0.44) GLSMAPTNPC1RAB9AALDH1A1
SCHEMBL3427899 0.83 PDE5A (0.50) GLSCCR2CHRNB2CHRNB4CHRNA3
SCHEMBL4076010 0.83 CHRNB2 (0.51) MAPK8CCR2CHRNB2CHRNB4CHRNA3
SCHEMBL3926548 0.81 ALDH1A1 (0.38) HSD11B1MAPTKDM4ELCKALDH1A1
SCHEMBL465792 0.80 CCR2 (0.42) GLSMAPK8CCR2CHRNB2CHRNB4
SCHEMBL30396325 0.80 CCR2 (0.42) GLSMAPK8CCR2CHRNB2CHRNB4
SCHEMBL6682298 0.80 CCR2 (0.41) GLSMAPK8CCR2CHRNB2CHRNB4
SCHEMBL29952585 0.80 CCR2 (0.42) GLSMAPK8CCR2CHRNB2CHRNB4
SCHEMBL3935616 0.80 CYP17A1 (0.38) HSD11B1MAPTKDM4ENPC1RAB9A
SCHEMBL1022260 0.79 GLS (0.42) GLSMAPK8CCR2CHRNB2CHRNB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482341-B2 N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-01-27 US disclosed
WO-2006037501-A9 ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES HOFFMANN LA ROCHE (CH) 2007-08-02 WO disclosed
EP-1799647-A1 ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES F.HOFFMANN-LA ROCHE AG (CH) 2007-06-27 EP disclosed
WO-2006037501-A1 ALKIL-PYRIDINES AS 11-BETA INHIBITORS FOR DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2006-04-13 WO disclosed
US-20060074237-A1 N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors HOFFMANN-LA ROCHE INC. 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074237-A1 N-(pyridin-2-yl)-benzenesulfonamides; hypotensive agents; antidiabetic agents for Type II Diabetes; obesity, eating disorders, dyslipidemia; 11beta-hydroxysteroid dehydrogenase inhibitors HSD3B1, HSD3B2, HSD11B2 HSD11B1 5/4885GLS 191/4885MAPK8 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.